Keeping you up to date on recent developments in neurology, including: Research suggests SARS-CoV-2 enters the brain; Technique developed to predict seizures; Machine intelligence improves brain mapping research; Hearing, blood sugar linked to cognitive function among older Latinos.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amgen, Antegene, Astrazeneca, Canbridge, Karyopharm, Novaremed, Novo Nordisk, Oyster Point, Polaryx, Synairgen.
As expected, the FDA's Vaccines and Related Biological Products Advisory Committee voted near-unanimously on Dec. 17, with one abstention, that available evidence shows the benefits of Moderna Inc.'s COVID-19 vaccine, mRNA-1273, outweigh its risks for people 18 and older. The vote bolsters the likelihood that the regulator will grant the vaccine an emergency use authorization (EUA), which could come as soon as Friday. Not the same as an approval, the authorization would allow for the vaccine's use for the prevention of COVID-19 in the U.S. even as further trials and regulatory evaluation remains underway ahead of a company BLA submission.
As COVID-19 cases surge across the U.S., there is growing demand for greater access to testing to rein in the pandemic. On Wednesday, the U.S. FDA granted an emergency use authorization (EUA) to Abbott Laboratories for at-home use of the company’s Binaxnow COVID-19 Ag Card Home Test. Abbott has teamed up with Miami-based telehealth provider Emed to distribute and administer the tests, with an expected 30 million in the first quarter of 2021.
Keeping you up to date on recent developments in diagnostics, including: Speeding triage of COVID-19 patients; New tests distinguishes COVID-19 and flu; Predicting heart failure; Expanding cryptosporidiosis testing in developing regions.
RSS
